Bristol-Myers Squibb – BMY

Growth of mega-blockbuster Plavix is helping <B>Bristol-Myers Squibb Company</B> (<a href=http://www.zacks.com/stock/quote/BMY>BMY</a>) drive EPS growth up near 16% in 2008. However, patent expirations loom large in Bristol&#39;s future starting in 2011 when the Plavix patent expires. <P ALIGN=&quot;left&quot;> That being said, the company does have an attractive mid-to-late-stage pipeline, and management has been dramatically working to reduce costs and shed less profitable and non-core businesses. We believe the company is an attractive take-over candiate at this level for a larger pharma name such as Sanofi or AstraZeneca. EPS growth through 2011 is near the top ofbig-pharma. <P ALIGN=&quot;left&quot;> We expect the shares to trade up near $27.

Comments

Leave a Reply